Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MLAB Stock Forecast 2026-2027
$94.68
Current Price
$522.88M
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MLAB Price Targets
+37.3%
To High Target of $130.00
+18.3%
To Median Target of $112.00
-0.7%
To Low Target of $94.00
MLAB Price Momentum
-0.7%
1 Week Change
-5.0%
1 Month Change
+19.8%
1 Year Change
+20.6%
Year-to-Date Change
-16.9%
From 52W High of $113.99
+70.7%
From 52W Low of $55.45
📊 TOP ANALYST CALLS
Did MLAB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mesa Labs is one of their latest high-conviction picks.
Latest MLAB Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, MLAB has a neutral consensus with a median price target of $112.00 (ranging from $94.00 to $130.00). The overall analyst rating is Buy (7.3/10). Currently trading at $94.68, the median forecast implies a 18.3% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Brandon Couillard at Wells Fargo, suggesting a 0.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MLAB Analyst Ratings
1
Buy
2
Hold
0
Sell
MLAB Price Target Range
Low
$94.00
Average
$112.00
High
$130.00
Current: $94.68
Latest MLAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MLAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 4, 2026 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $94.00 |
| Dec 15, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Aug 8, 2025 | Wells Fargo | Equal-Weight | Upgrade | $N/A | |
| May 30, 2025 | Wells Fargo | Underweight | Maintains | $N/A | |
| Oct 1, 2024 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Aug 27, 2024 | Wells Fargo | Underweight | Initiates | $N/A | |
| Aug 6, 2024 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Jul 2, 2024 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Apr 4, 2024 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Jan 4, 2024 | Evercore ISI Group | Outperform | Upgrade | $N/A | |
| Jan 4, 2021 | Evercore ISI Group | In-Line | Downgrade | $N/A | |
| Nov 10, 2020 | Keybanc | Sector Weight | Initiates | $N/A | |
| Nov 10, 2020 | KeyBanc | Sector Weight | Initiates | $N/A | |
| Oct 2, 2020 | JP Morgan | Neutral | Initiates | $N/A | |
| Dec 4, 2019 | Jefferies | Buy | Initiates | $N/A | |
| Aug 26, 2019 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Jun 10, 2016 | Sidoti & Co. | Neutral | Downgrade | $N/A | |
| Feb 10, 2016 | Janney Capital | Buy | Initiates | $N/A | |
| Feb 10, 2016 | Janney Montgomery Scott | Buy | Initiates | $N/A |
Mesa Laboratories Inc. (MLAB) Competitors
The following stocks are similar to Mesa Labs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mesa Laboratories Inc. (MLAB) Financial Data
Mesa Laboratories Inc. has a market capitalization of $522.88M with a P/E ratio of 77.4x. The company generates $249.13M in trailing twelve-month revenue with a 2.7% profit margin.
Revenue growth is +2.6% quarter-over-quarter, while maintaining an operating margin of +4.3% and return on equity of +3.9%.
Valuation Metrics
Market Cap
$522.88M
Enterprise Value
$664.85M
P/E Ratio
77.4x
PEG Ratio
-1.8x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
+2.6%
Gross Margin
+66.2%
Operating Margin
+4.3%
Net Margin
+2.7%
EPS Growth
+2.6%
Financial Health
Cash/Price Ratio
+5.5%
Current Ratio
1.7x
Debt/Equity
90.7x
ROE
+3.9%
ROA
+2.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mesa Laboratories Inc. (MLAB) Business Model
About Mesa Laboratories Inc.
What They Do
Manufactures critical equipment for regulated industries.
Business Model
The company generates revenue by developing and selling precision instruments and consumables tailored for regulated sectors such as healthcare, pharmaceuticals, and food and beverage. Its focus on compliance and quality assurance allows it to serve customers who require reliable monitoring and sterilization products, thereby creating a steady demand for its offerings.
Additional Information
Founded in 1982 and based in Lakewood, Colorado, Mesa Laboratories is known for its innovation and reliability. The company is committed to expanding its product lines through strategic acquisitions and ongoing research and development, positioning itself as a key player in ensuring industry compliance and product safety.
Company Information
Sector
Technology
Industry
Scientific & Technical Instruments
Employees
717
CEO
Dr. Siddhartha Chandrakant Kadia B.E., M.S., Ph.D.
Country
United States
IPO Year
1995
Website
www.mesalabs.comMesa Laboratories Inc. (MLAB) Latest News & Analysis
Latest News
MESA LABS DECLARES QUARTERLY DIVIDEND
9 days ago
Quick Summary
Mesa Laboratories, Inc. (NASDAQ: MLAB) has declared a quarterly dividend of $0.16 per share, payable on September 15, 2026, to shareholders of record on August 31, 2026.
Why It Matters
Mesa Laboratories' dividend declaration indicates financial stability and returns for shareholders, potentially attracting income-focused investors and positively impacting stock price.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mesa Laboratories' Q4 fiscal 2026 results showed sales and earnings below Wall Street expectations, though adjusted operating income experienced strong growth.
Why It Matters
Mesa Laboratories' missed earnings expectations may signal potential weaknesses, impacting investor confidence, while strong adjusted operating income growth suggests resilience and future opportunity.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Mesa Laboratories, Inc. (NASDAQ:MLAB) reported its 4Q26 and FY26 results for the period ending March 31, 2026. Further financial details were not included in the excerpt.
Why It Matters
Mesa Laboratories' quarterly and annual financial results can impact stock performance, indicating growth or challenges in the life sciences sector, influencing investor sentiment and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
2 months ago
Quick Summary
Mesa Laboratories, Inc. (NASDAQ:MLAB) will release its Q4 and fiscal year financial results on May 27, 2026, at 6:00 A.M. ET.
Why It Matters
Mesa Laboratories' upcoming financial results announcement could impact stock valuation, investor sentiment, and market expectations, influencing trading decisions and company performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Royce Small-Cap Fund FY 2025: What Worked
4 months ago
Quick Summary
In 2025, five of the Fund's 10 equity sectors contributed positively, particularly Industrials, Financials, and IT. Alamos Gold saw a stock rise due to a strong earnings outlook and buyback program, with Q1 revenue up 48% YoY.
Why It Matters
Strong performance in key sectors and Alamos Gold's revenue growth signal potential investment opportunities, while rising gold prices and buybacks may enhance shareholder value.
Source: Seeking Alpha
Market Sentiment:
Positive
Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
6 months ago
Quick Summary
Mesa Laboratories, Inc. (MLAB) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting key developments and insights for investors.
Why It Matters
Mesa Laboratories’ presentation at a major healthcare conference highlights its strategic initiatives and growth potential, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About MLAB Stock
What is Mesa Laboratories Inc.'s (MLAB) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Mesa Laboratories Inc. (MLAB) has a median price target of $112.00. The highest price target is $130.00 and the lowest is $94.00.
Is MLAB stock a good investment in 2027?
According to current analyst ratings, MLAB has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $94.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MLAB stock?
Wall Street analysts predict MLAB stock could reach $112.00 in the next 12 months. This represents a 18.3% increase from the current price of $94.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mesa Laboratories Inc.'s business model?
The company generates revenue by developing and selling precision instruments and consumables tailored for regulated sectors such as healthcare, pharmaceuticals, and food and beverage. Its focus on compliance and quality assurance allows it to serve customers who require reliable monitoring and sterilization products, thereby creating a steady demand for its offerings.
What is the highest forecasted price for MLAB Mesa Laboratories Inc.?
The highest price target for MLAB is $130.00 from at , which represents a 37.3% increase from the current price of $94.68.
What is the lowest forecasted price for MLAB Mesa Laboratories Inc.?
The lowest price target for MLAB is $94.00 from Brandon Couillard at Wells Fargo, which represents a -0.7% decrease from the current price of $94.68.
What is the overall MLAB consensus from analysts for Mesa Laboratories Inc.?
The overall analyst consensus for MLAB is neutral. Out of 2 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $112.00.
How accurate are MLAB stock price projections?
Stock price projections, including those for Mesa Laboratories Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:46 AM UTC